[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hpv":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HPV",68,60,[8,16,22,29,35,41,47,53,59,65,72,78,84,90,96,102,108,114,120,127,133,139,145,152,158,164,170,176,182,188,194,200,206,212,218,224,230,236,242,248,254,260,266,272,278,284,290,296,302,308],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07178301","Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:15:58.452248Z","2026-07-19T19:36:05.065224Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06210854","Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16\u002F18+",[12],"2026-08-26T02:19:29.922117Z","2026-07-05T05:32:16.748142Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06315257","A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients",[26],"Phase 1","2026-08-26T02:18:58.958025Z","2026-06-16T05:54:07.916994Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07601074","A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)",[12],"2026-08-26T02:15:34.659160Z","2026-06-04T01:30:07.904084Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06984861","A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:29.643338Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05268614","Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.512737Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06554158","De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers",[],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:29.477332Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06223568","Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer",[12],"2026-08-03T03:13:22.003666Z","2026-05-05T02:43:29.471790Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT06693323","Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W\u002F SOC Tx for HPV+ Pts W\u002F HNSCC",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.382550Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":70,"content_modified":71},"NCT06385080","A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer",[69],"Phase 1\u002FPhase 2","2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.372476Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06607406","Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery",[],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.183951Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06702033","The Minimalist Trial-2",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:29.138139Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06157151","PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer",[12],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:29.077130Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03215719","Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:29.074089Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06769698","A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:29.044914Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06912087","Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC",[26],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.015140Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w\u002FHPV H&N Ca",[12],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:28.875169Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05419089","The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)",[12],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.852988Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":125,"content_modified":126},"NCT04645602","Merck IIT: RRP Pembro and Lenvatinib",[124],"Early Phase 1","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:28.823117Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05541016","De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.485078Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT05894083","A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.218746Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05799144","pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w\u002FAdvanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer",[12],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.217841Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":150,"content_modified":151},"NCT06563479","A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer",[149],"Phase 3","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.989005Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT07063212","A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)",[12],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:27.834863Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT07044635","Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.806024Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06206564","Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants",[12],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:27.672268Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT05962242","HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.631667Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:27.405933Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:27.316218Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT07317154","Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients",[26],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.309918Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT07281417","Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma",[12],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.296323Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2\u002F3)",[12],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.262617Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT06699212","A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases",[149],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:27.037240Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT07290621","Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:26.936724Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)",[12],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716941Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT07214987","PDT For Induction Therapy For Head And Neck Cancer",[12],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:26.678204Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT04900623","Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study",[12],"2026-08-26T02:16:00.194860Z","2026-05-05T02:35:31.906438Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT06445114","Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:27.435233Z","2026-04-29T02:57:57.120187Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT05526924","Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer",[26],"2026-08-26T02:15:30.699880Z","2026-04-29T02:57:57.066191Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT07209189","Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:28.214027Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT06319963","A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer",[69],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.173901Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT05172245","Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer",[26],"2026-08-26T02:17:41.695983Z","2026-07-19T19:36:05.120891Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT05686226","E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",[12],"2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.812867Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":276,"content_modified":277},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[69],"2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":279,"title":280,"phases":281,"status":13,"updated_at":282,"content_modified":283},"NCT06021626","A Study of CRD3874-SI in People With Solid Tumors",[26],"2026-08-26T02:16:32.589113Z","2026-07-05T05:32:16.744495Z",{"nct_id":285,"title":286,"phases":287,"status":13,"updated_at":288,"content_modified":289},"NCT07205718","A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors",[69],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:29.041246Z",{"nct_id":291,"title":292,"phases":293,"status":13,"updated_at":294,"content_modified":295},"NCT07281430","Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)",[],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.709835Z",{"nct_id":297,"title":298,"phases":299,"status":13,"updated_at":300,"content_modified":301},"NCT07060261","Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma",[],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.283097Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT05372484","Rice Technologies for Cervical Cancer Screening and Diagnosis",[],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.060298Z",{"nct_id":309,"title":310,"phases":311,"status":13,"updated_at":312,"content_modified":313},"NCT05606133","Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers",[],"2026-08-26T02:18:18.766496Z","2026-05-05T02:35:31.867815Z"]